Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Aug 1;111(8):749-750.
doi: 10.1093/jnci/djz096.

Sex-Related Effect on Immunotherapy Response: Implications and Opportunities

Leandro Machado Colli  1 , Lindsay M Morton  1 , Stephen J Chanock  1
Affiliations
Editorial

Sex-Related Effect on Immunotherapy Response: Implications and Opportunities

Leandro Machado Colli et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Mellman I, Coukos G, Dranoff G.. Cancer immunotherapy comes of age. Nature. 2011;4807378:480–489. - PMC - PubMed
    1. Haslam A, Prasad V.. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;25:e192535.. - PMC - PubMed
    1. Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials [published online ahead of print April 25, 2019.]. JAMA Oncol. 2019;doi: 10.1001/jamaoncol.2019.0393. - PMC - PubMed
    1. Havel JJ, Chowell D, Chan TA.. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;193:133–150. - PMC - PubMed
    1. Conforti F, Pala L, Bagnardi V, et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J Natl Cancer Inst. 2019;1118:772–781. - PMC - PubMed

Substances